Clinical translation potential from animal to human in Alzheimer's Disease

Registration ID: IJNRD_197549

Published ID: IJNRD2305849

: Click Here to Get

Eshani Mahajan

Keywords: Alzheimer's disease, Amyloid beta, Acetylcholinesterase inhibitors, preclinical studies, clinical trials, pathophysiology

Alzheimer's disease (AD) is a chronic, progressive, and neurodegenerative disorder. Five drugs approved by FDA to treat Alzheimer's disease. The first four are Donepezil, Memantine, Rivastigmine, and Galantamine. The fifth one is a fixed dose combination of Memantine as well as Donepezil. All these drugs treat Alzheimer's only symptomatically. So, there is an urgent need to investigate a drug that can provide both symptomatic as well as curative treatment for Alzheimer's. Huge experimental research is going on but still, there is a lack of translation potential of experimental data into clinics. Various factors are responsible for this which include lack of efficacy, severe adverse effects, complex genetics, difficulty in the recruitment process of AD clinical trials, lack of understanding of the disease pathology, or complex pathophysiology of the disease. There are various ways to address these challenges in dementia research which include increasing the funding for dementia research, increase in public awareness of AD and other dementia, incorporating dementia research into the care continuum, improving access to clinical trials, and decreasing risks of the drug development process of AD. Therefore, in this review, preclinical limitations which hamper the drug development process for the treatment of Alzheimer's disease are summarized.

Published Paper   E-Certificate

Eshani Mahajan (June-2023). Clinical translation potential from animal to human in Alzheimer's Disease. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(5), i369-i393. https://ijnrd.org/papers/IJNRD2305849.pdf

Volume 8 Issue 5, June-2023

Pages : i369-i393

Paper Reg. ID: IJNRD_197549

Published Paper Id: IJNRD2305849

Downloads: 000122253

Research Area: Medical Science

Author Type: Indian Author

Country: Chandigarh , Chandigarh , India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2305849.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2305849

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

UGC CARE JOURNAL PUBLICATION | ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

© 2025 — Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License. and The Open Definition.

You are free to share, adapt, and redistribute the material, provided proper credit is given to the original author. 🛡️ Disclaimer: The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.

Call For Paper - Volume 10 | Issue 12 | December 2025

IJNRD is a Scholarly Open Access, Peer-Reviewed, Refereed, and UGC CARE Journal Publication with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost, and Transparent Peer Review Journal Publication that adheres to the UGC CARE 2025 Peer-Reviewed Journal Policy and aligns with Scopus Journal Publication standards to ensure the highest level of research quality and credibility.

IJNRD offers comprehensive Journal Publication Services including indexing in all major databases and metadata repositories, Digital Object Identifier (Crossref DOI) assignment for each published article with additional fees, citation generation tools, and full Open Access visibility to enhance global research reach and citation impact.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse academic and professional fields. The journal promotes global knowledge exchange among researchers, developers, academicians, engineers, and practitioners, serving as a trusted platform for innovative, peer-reviewed journal publication and scientific collaboration.

Indexing Coverage: Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many other recognized academic repositories.

How to submit the paper?

By Our website

Click Here to Submit Paper Online

By Mail

Send your paper to editor@ijnrd.org

You can now publish your research in IJNRD. IJNRD is a Transparent Peer-Reviewed Open Access Journal Publication (Refereed Journal), aligning with New UGC and UGC CARE recommendations.

For more details, refer to the official notice: UGC Public Notice

Submit Paper Online

Important Dates for Current issue

Paper Submission Open For: December 2025

Current Issue: Volume 10 | Issue 12 | December 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Dec-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details

Approval, Licenses and Indexing: More Details